Table S1 Clinicopathologic characteristics of prostate cancer patients (Cohort 1+2)

| Patient Characteristics | CRPC-Adeno | CRPC-NE |
|-------------------------|------------|---------|
| Number of patients      | 39         | 8       |
| Median age at diagnosis in years (range) | 65 (45-80) | 63 (57-67) |
| Median age at death in years (range) | 72 (53-90) | 71 (60-87) |
| Median survival after diagnosis in years (range) | 8 (1-25) | 5 (1-13) |
| Median PSA at death in ng/mL (range) | 620.5 (5.63-15000) | 3.3 (0.15-86.3) |
| Race: Caucasians (C) Others including African American, Hispanics, Asians (O) | C-34 O-5 | C-7* |

Gleason Score

| Gleason Score | CRPC-Adeno | CRPC-NE |
|---------------|------------|---------|
| 4-6           | 5          | 1       |
| 7             | 17         | 2       |
| 8-10          | 15         | 5       |
| Unknown       | 2          | -       |

Metastatic sites

| Metastatic sites | CRPC-Adeno | CRPC-NE |
|------------------|------------|---------|
| Lung             | 4          | 2       |
| Liver            | 10         | 1       |
| Lymph node (LN)  | 10         | 1       |
| Others           | 15         | 4       |

Androgen Ablation Therapy
Number of patients receiving androgen ablation therapy (%) | 39 (100) | 8 (100) 
---|---|---
Number of patients receiving Enzalutamide, Abiraterone or both (%) | 9 (23) | 2 (25) 

**Other Therapies**

Ketoconazole (%) | 18 (46) | 1 (13) 
DES (%) | 15 (38) | 1 (13) 
Corticosteroids (%) | 30 (77) | 4 (50) 
Estramustine (%) | 5 (13) | 1 (13) 
Taxotere (%) | 31 | 79 | 4 (50) 

*Race not known for 1 case*